Recent development of therapeutics for chronic HCV infection
Authors:
- Zhuhui HuangZHZhuhui Huang
- Michael G. MurrayMMMichael G. Murray
- John A. SecristJSJohn A. Secrist
- 1 September 2006
- journal article
- review article
- Published by Elsevier in Antiviral Research
- Vol. 71 (2-3) , 351-362
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- 750 Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical developmentJournal of Hepatology, 2006
- Hepatitis C virus NS3-4A serine protease inhibitors: Use of a P2–P1 cyclopropyl alanine combination for improved potencyBioorganic & Medicinal Chemistry Letters, 2005
- Hepatitis C virus NS3-4A serine protease inhibitors: SAR of moiety with improved potencyBioorganic & Medicinal Chemistry Letters, 2005
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005
- Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potencyBioorganic & Medicinal Chemistry Letters, 2004
- Characterization of the Inhibition of Hepatitis C Virus RNA Replication by NonnucleosidesJournal of Virology, 2004
- The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061—From the NMR tube to the clinicPeptide Science, 2004
- Mechanismof Action and Antiviral Activity of Benzimidazole-Based AllostericInhibitors of the Hepatitis C Virus RNA-Dependent RNAPolymeraseJournal of Virology, 2003
- The identification of α-ketoamides as potent inhibitors of hepatitis c virus nS3-4a proteinaseBioorganic & Medicinal Chemistry Letters, 2001
- Interferon Alfacon-1Drugs, 2001